News | Information Technology | February 04, 2020

Qynapse Receives FDA Clearance for QyScore Imaging Software

QyScore allows automated quantification of a broad portfolio of MRI markers that are key to support early diagnosis and clinical monitoring of neurodegenerative disorders

Qynapse, a medical technology company, announced that it received U.S. Food and Drug Administration (FDA) 510(k) clearance for its QyScore software

February 4, 2020 — Qynapse, a medical technology company, announced that it received U.S. Food and Drug Administration (FDA) 510(k) clearance for its QyScore software.

 

QyScore provides robust and precise analyses of brain MRI markers that intervene early in the process of neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease or multiple sclerosis.

 

The software combines an advanced user interface with patient reports that are generated automatically in minutes. The results are presented in comparison to a healthy subjects database, supporting neurologists and radiologists in their clinical decision-making. QyScore® is compatible with the clinical routine workflow to support differential diagnosis and measure of clinical progression and also used in clinical trials for monitoring of drug efficacy and safety.

 

According to Bruno Dubois, professor of neurology at Sorbonne University, and director of the Memory and Alzheimer’s Disease Institute (IM2A) at Pitié Salpêtrière Hospital in Paris, “QyScore makes a difference for the diagnosis of dementias at an early stage of the disease when it remains a challenge. The automatic quantification of markers such as brain atrophy, white matter hyperintensities and more, provides highly valuable help to support a timely diagnosis and an efficient monitoring of disease progression.”

 

The software demonstrates its value by quantifying longitudinal changes of regions of interest in the brain, eliminating the inter- and intra-rater variability in images reading, and reducing the time and cost of image analysis.

 

Commercialization of QyScore started in Europe following the CE mark approval in September 2017.

 

“FDA clearance is a major milestone to expand the commercialization of the software within the U.S.,” said Olivier Courrèges, CEO of Qynapse. “Qynapse will accelerate collaboration with experts and healthcare providers in the U.S. to pursue its journey for better patient care in neurology.”

 

For more information: www.qynapse.com/

Related Content

Sponsored Content | Videos | Artificial Intelligence | February 21, 2020
In Artificial Intelligence at RSNA 2019, ITN Contributing Editor Greg Freiherr offers an overview of artificial intel
An example of the MRI scans showing long-term and short-term survival indications. #MRI

An example of the MRI scans showing long-term and short-term survival indications. Image courtesy of Case Western Reserve University

News | Magnetic Resonance Imaging (MRI) | February 21, 2020
February 21, 2020 — ...
A cutting-edge magnet resonance imaging (MRI) technique to detect iron deposits in different brain regions can track declines in thinking, memory and movement in people with Parkinson's disease #Parkinsons #MRI

Summary steps of the processing pipeline for QSM reconstruction (phase pre-processing and map estimation) and whole brain/regional analysis. ANTs, advanced normalisation tools; MP-RAGE, magnetisation-prepared, 3D, rapid, gradient-echo; MSDI, multi-scale dipole inversion; QSM, quantitative susceptibility mapping; ROI, region of interest; SWI, susceptibility weighted imaging.

News | Magnetic Resonance Imaging (MRI) | February 21, 2020
February 21, 2020 — A cutting-edge...
Altamont’s zero-footprint solution, CaptureWare, allows Mach7’s Enterprise Imaging Platform (EIP) to ingest more DICOM and/or non-DICOM data from various sources in a facility
News | PACS | February 20, 2020
February 20, 2020 — Mach7 announced its partnership with Altamont
Two magnetic resonance imaging (MRI) findings — joint capsule edema and thickness at the axillary recess, specifically — proved useful in predicting stiff shoulder in patients with rotator cuff tears, according to an ahead-of-print article in the May issue of the American Journal of Roentgenology (AJR)

A: Oblique coronal fat-suppressed T2-weighted MR image shows normal hypointense joint capsule at axillary recess (arrow). Note full-thickness tear of supraspinatus tendon (arrowheads) B: Oblique sagittal proton density MR image shows preserved subcoracoid fat triangle (asterisk). Image courtesy of the American Journal of Roentgenology (AJR)

News | Magnetic Resonance Imaging (MRI) | February 20, 2020
February 20, 2020 — Two ma...
Sponsored Content | Videos | Enterprise Imaging | February 19, 2020
Bill Lacy, vice president, Medical Informatics at FUJIFILM Medic...
Hyperfine Research, Inc. announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the world’s first bedside Magnetic Resonance Imaging (MRI) system

Hyperfine's point-of-care MRI wheels directly to the patient’s bedside, plugs into a standard electrical wall outlet, and is controlled via a wireless tablet. Photo courtesy of Business Wire

News | Magnetic Resonance Imaging (MRI) | February 12, 2020
February 12, 2020 — Hyperfine Research, Inc. announced that i
The Candelis ImageGrid Plus PACS Server is an ultra-high-performance platform that can support high volume healthcare environments of 1,000 plus modalities
News | PACS | February 12, 2020
February 12, 2020 — The Candelis ImageGrid Plus...